Search

Your search keyword '"Durot, Eric"' showing total 230 results

Search Constraints

Start Over You searched for: Author "Durot, Eric" Remove constraint Author: "Durot, Eric"
230 results on '"Durot, Eric"'

Search Results

1. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

2. Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study

4. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

6. Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE

7. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma

8. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

10. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

11. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia

12. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

13. High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia

14. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

16. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

17. A revised international prognostic score system for Waldenström’s macroglobulinemia

18. Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.

22. Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab

23. Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

25. Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

27. High PDL1/PDL2gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma

28. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

30. P-169: Bendamustine rituximab primary therapy for Waldenström Macroglobulinemia: an international, multicenter collaborative study

31. “Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain

32. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)

34. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

35. Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.

36. High frequency of central nervous system involvement in transformed Waldenstrom macroglobulinemia

38. Computed Tomography-Based Texture Analysis as a Predictor of Survival in Patients with T-Cell Lymphomas.

44. Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

45. Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

46. A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

47. High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

48. Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Catalog

Books, media, physical & digital resources